Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Dentatorubral-Pallidoluysian Atrophy

In brief

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with dentatorubral-pallidoluysian atrophy (DRPLA) due to a heterozygous pathogenic CAG trinucleotide expansion in ATN1

Key facts

Study ID

NCT06706388

Run by

n-Lorem Foundation

People needed

1

Starts

2024-02-21

Expected to finish

2027-02-01

Last updated by the study team

2026-04-09

Who can join

Age: 17 and older, up to 17. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s).
• Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records.
• Genetically confirmed Dentatorubral-pallidoluysian atrophy (DRPLA) due to ATN1 mutation

You may not qualify if…

• Use of investigational medication within 5 half-lives of the drug at enrolment
• Participant has any condition that in the opinion of the Site Investigator, would ultimately prevent the completion of study procedures.

Where it is running

• Columbia University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.